Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)-positive, advanced non -small cell lung cancer (NSCLC) that progressed on alectinib or ceritinib.

被引：3

作者：

Kim, Edward S.

Ou, Sai-Hong Ignatius

Barlesi, Fabrice

Mok, Tony S. K.

Ahn, Myung-Ju

Bunn, Veronica

Zhang, Pingkuan

机构：

[1] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[2] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Sch Med, Orange, CA 92668 USA

[3] Aix Marseille Univ, APHM, CEPCM CLIP2, INSERM,CNRS,CRCM, Marseille, France

[4] Prince Wales Hosp, Shatin, Hong Kong, Peoples R China

[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[6] Millennium Pharmaceut Inc, Cambridge, MA USA

来源：

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.TPS9115

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS9115

引用

页数：1